Search for: "TEVA PHARMACEUTICALS USA, INC."
Results 141 - 160
of 481
Sort by Relevance
|
Sort by Date
19 Oct 2017, 7:36 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED October 16, 2017, Order) (Bryson, CJ) [read post]
16 Oct 2017, 12:36 pm
Teva Pharmaceuticals USA Inc. [read post]
24 Sep 2017, 5:04 pm
Teva Pharmaceuticals USA, Inc. [read post]
29 Aug 2017, 7:35 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED August 25, 2017, Order) (Bryson, CJ) [read post]
20 Jul 2017, 12:47 pm
On July 7, 2017, Teva Pharmaceuticals USA, Inc. filed a complaint in the Eastern District of Pennsylvania alleging that a former executive disclosed confidential information to a romantic partner who happens to be an executive of one of Teva’s direct competitors. [read post]
20 Jul 2017, 12:47 pm
On July 7, 2017, Teva Pharmaceuticals USA, Inc. filed a complaint in the Eastern District of Pennsylvania alleging that a former executive disclosed confidential information to a romantic partner who happens to be an executive of one of Teva’s direct competitors. [read post]
17 Jul 2017, 9:41 am
USA,Inc., 752 F.3d 967, 973 (Fed. [read post]
26 Jun 2017, 7:51 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit panel of Judges Dyk, Mayer and O’Malley determined: “after the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale” for the sale to be invalidating. [read post]
25 Jun 2017, 9:25 pm
District Court for the District of Delaware issued a Memorandum Order that, inter alia, overruled objections by Defendants Glenmark Pharmaceuticals Inc., USA and Teva Pharmaceuticals USA, Inc. to a Report and Recommendation issued by Magistrate Judge Burke and adopted the Report. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
8 Jun 2017, 3:27 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
28 May 2017, 8:19 pm
Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. [read post]
25 May 2017, 6:20 pm
Sandoz, Inc., 749 F. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
1 May 2017, 12:44 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit panel of Judges Dyk, Mayer and O’Malley determined: “after the AIA, if the […] The post CAFC Interprets AIA On-Sale Bar: Invention details need not be public for sale to be invalidating appeared first on... [read post]
12 Apr 2017, 10:32 am
Defendants are Actavis LLC of Parsippany, New Jersey; Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania; and Teva Pharmaceutical Industries, Ltd. of Petach Tikva, Israel. [read post]
12 Apr 2017, 10:32 am
Defendants are Actavis LLC of Parsippany, New Jersey; Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania; and Teva Pharmaceutical Industries, Ltd. of Petach Tikva, Israel. [read post]
12 Apr 2017, 7:13 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED April 10, 2017, Order) (Bryson, CJ) [read post]
